AdvaMed Wary Of Japan's Ability To Improve Incremental Product Review
This article was originally published in PharmAsia News
Japan is in need of device industry investment, but without the incentive of data exclusivity, the government needs to counter existing disincentives, says AdvaMed CEO.
You may also be interested in...
Companies selling medical devices in Japan will be notified in the next few weeks of payment rate reductions for their products following the recent release of reimbursement rules for the 2010-2012 cycle
Japan is rolling out a new three-track medical device review system based on the novelty of the product, Japanese device reviewers said